Doxycycline Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Antibacterial
Subclass
Tetracycline antibiotic
Speciality
Infectious Diseases
Schedule (India)
Schedule H
Routes
Oral, Intravenous
Formulations
| Form | Strengths |
|---|---|
| Capsules | 100 mg |
| Tablets | 100 mg |
| Dispersible tablets | 100 mg |
| Tablets (extended-release) | 40 mg (sub-antimicrobial dose for rosacea) |
| Injection (powder for reconstitution) | 100 mg/vial |
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Scrub Typhus / Rickettsial Infections
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | 7 days (extend to 14 days if severe or delayed response) |
| Clinical notes | First-line therapy per ICMR/NCDC guidelines; continue until afebrile for 48–72 hours; highly endemic in Himalayan foothills, NE India, South India |
2. Cholera
| Parameter | Recommendation |
|---|---|
| Starting dose | 300 mg single dose OR 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily if multi-dose regimen |
| Maximum dose | 300 mg/day |
| Duration | Single dose or 3 days |
| Clinical notes | Adjunct to ORS; reduces stool output and vibrio shedding; per NCDC outbreak guidelines |
3. Uncomplicated Genital Chlamydia Infection
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | 7 days |
| Clinical notes | First-line per NACO STI guidelines; treat partner simultaneously; test-of-cure not routinely needed |
4. Non-Gonococcal Urethritis / Cervicitis
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | 7 days |
| Clinical notes | Covers Chlamydia and Mycoplasma genitalium; combine with ceftriaxone if gonorrhoea not excluded |
5. Pelvic Inflammatory Disease (PID)
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | 14 days |
| Clinical notes | Use with ceftriaxone 250 mg IM single dose ± metronidazole 500 mg twice daily; per NACO syndromic management guidelines |
6. Leptospirosis (Mild–Moderate)
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | 7 days |
| Clinical notes | Effective if started within first 4 days of illness; IV penicillin preferred for severe/icteric disease |
7. Brucellosis
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | 6 weeks |
| Clinical notes | Always combine with streptomycin (first 2–3 weeks) OR rifampicin (full 6 weeks); monotherapy leads to high relapse |
8. Malaria Chemoprophylaxis
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg once daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg once daily |
| Maximum dose | 100 mg/day |
| Duration | Start 1–2 days before travel; continue during stay + 4 weeks after leaving endemic area |
| Clinical notes | Use when mefloquine/atovaquone-proguanil contraindicated or unavailable; not for treatment of acute malaria as monotherapy |
9. Severe Malaria (Adjunct Therapy)
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | 7 days |
| Clinical notes | Always combine with IV artesunate or quinine; never use as monotherapy; per NVBDCP guidelines |
10. Acne Vulgaris (Moderate–Severe Inflammatory)
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg once daily OR 50 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 50–100 mg once daily |
| Maximum dose | 100 mg/day |
| Duration | 6–12 weeks (reassess; avoid prolonged use >3–4 months) |
| Clinical notes | Second-line after topical therapy fails; combine with topical retinoid and benzoyl peroxide; taper to sub-antimicrobial dose or stop once controlled |
11. Rosacea (Papulopustular)
| Parameter | Recommendation |
|---|---|
| Starting dose | 40 mg once daily (modified-release) OR 50 mg once daily (immediate-release) |
| Titration | Not applicable |
| Usual maintenance dose | 40–50 mg once daily |
| Maximum dose | 100 mg/day (if 40 mg insufficient) |
| Duration | 8–16 weeks |
| Clinical notes | Sub-antimicrobial dosing preferred to minimise resistance; combine with topical metronidazole or azelaic acid |
12. Community-Acquired Pneumonia (Atypical Pathogens)
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | 7–14 days |
| Clinical notes | Covers Mycoplasma, Chlamydophila, Legionella; use as monotherapy only for mild atypical pneumonia; combine with beta-lactam for moderate–severe CAP |
13. Q Fever (Coxiella burnetii)
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | Acute: 14 days; Chronic (endocarditis): 18–24 months with hydroxychloroquine |
| Clinical notes | Chronic Q fever requires specialist management; add hydroxychloroquine to enhance intracellular killing |
14. Plague (Yersinia pestis)
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily OR 200 mg once daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | 10–14 days |
| Clinical notes | Alternative to streptomycin/gentamicin; per NCDC outbreak protocols; strict infection control required |
15. Anthrax (Post-Exposure Prophylaxis & Cutaneous)
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | PEP: 60 days; Cutaneous: 7–10 days |
| Clinical notes | Ciprofloxacin is alternative first-line; for inhalational/systemic anthrax, use IV doxycycline in multidrug regimen |
16. Lymphogranuloma Venereum (LGV)
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | 21 days |
| Clinical notes | Per NACO guidelines; azithromycin is alternative; aspirate fluctuant buboes (do not incise) |
17. Granuloma Inguinale (Donovanosis)
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 100 mg twice daily |
| Maximum dose | 200 mg/day |
| Duration | Minimum 3 weeks; continue until complete epithelialisation |
| Clinical notes | Endemic in parts of India; azithromycin is alternative; prolonged treatment often required |
18. Periodontitis (Adjunctive Therapy)
| Parameter | Recommendation |
|---|---|
| Starting dose | 20 mg twice daily (sub-antimicrobial dose) |
| Titration | Not applicable |
| Usual maintenance dose | 20 mg twice daily |
| Maximum dose | 40 mg/day |
| Duration | Up to 9 months |
| Clinical notes | Adjunct to scaling/root planing; anti-collagenase effect at sub-antimicrobial dose; does not promote resistance |
Secondary Indications — Adults (Off-label)
| MRSA skin/soft tissue infection | 100 mg twice daily | 5–10 days | RCT data; Indian dermatology practice | OFF-LABEL; alternative when TMP-SMX unavailable |
|---|---|---|---|---|
|
Small intestinal bacterial overgrowth (SIBO)
|
100 mg twice daily | 7–10 days | Limited RCT data | OFF-LABEL; Specialist only; when rifaximin unavailable |
|
Early Lyme disease (if documented travel history)
|
100 mg twice daily | 14–21 days | International guidelines; rare in India | OFF-LABEL; very rare in India; confirm exposure history |
|
Ehrlichiosis / Anaplasmosis
|
100 mg twice daily | 7–14 days | Case reports; travel-related | OFF-LABEL; empiric for tick-borne illness with travel history |
|
Pleural effusion sclerotherapy
|
500 mg in 30–50 mL NS intrapleurally | Single instillation | RCTs; Indian pulmonology practice | OFF-LABEL; Specialist only; for recurrent malignant effusions |
|
Bullous pemphigoid (steroid-sparing)
|
100–200 mg/day | Months | RCT evidence (BLISTER trial) | OFF-LABEL; Specialist only; with topical steroids |
|
Chronic prostatitis (Category II/III)
|
100 mg twice daily | 4–6 weeks | Urology practice | OFF-LABEL; when atypical organisms suspected |
PAEDIATRIC DOSING (Specialist Only)
⚠️ Age Restriction
- Generally avoided in children <8 years due to risk of permanent teeth staining and enamel hypoplasia
- Exception: May be used in children <8 years for life-threatening infections (scrub typhus, Rocky Mountain spotted fever, anthrax, severe malaria) when benefits outweigh risks — specialist supervision mandatory
- Recent evidence suggests short courses (≤21 days) may have minimal dental effects, but caution persists in Indian practice
Weight-Based Dosing (Children ≥8 years)
| Weight Category | Loading Dose (Day 1) | Maintenance Dose | Maximum Daily Dose |
|---|---|---|---|
| <45 kg | 4 mg/kg (divided q12h) | 2–4 mg/kg/day (single or divided) | 200 mg/day |
| ≥45 kg | Adult dosing applies | 100 mg once or twice daily | 200 mg/day |
Primary Paediatric Indications
1. Scrub Typhus / Rickettsial Disease
| Parameter | Children ≥8 years | Children <8 years (life-threatening only) |
|---|---|---|
| Dose | 2.2 mg/kg twice daily (max 100 mg/dose) | 2.2 mg/kg twice daily (max 100 mg/dose) |
| Duration | 7 days or until afebrile 48–72 hours | 5–7 days (shortest effective course) |
| Notes | First-line per IAP/ICMR | Specialist only; benefits outweigh dental risk in severe disease |
2. Malaria Chemoprophylaxis
| Parameter | Recommendation |
|---|---|
| Minimum age | ≥8 years |
| Dose | 2 mg/kg once daily (max 100 mg) |
| Duration | 1–2 days before travel through 4 weeks after |
| Notes | Alternative when atovaquone-proguanil unavailable |
3. Severe Malaria (Adjunct)
| Parameter | Recommendation |
|---|---|
| Age | ≥8 years (or <8 years if benefits outweigh risks) |
| Dose | 2.2 mg/kg twice daily (max 100 mg/dose) |
| Duration | 7 days |
| Notes | Always combine with IV artesunate; never monotherapy |
4. Cholera
| Parameter | Recommendation |
|---|---|
| Age | ≥8 years |
| Dose | 2–4 mg/kg/day in single or divided doses |
| Duration | Single dose or 3 days |
| Notes | Adjunct to ORS; reduces disease duration |
5. Anthrax (Post-Exposure Prophylaxis)
| Parameter | Recommendation |
|---|---|
| Age | Any age (including <8 years due to severity) |
| Dose | 2.2 mg/kg twice daily (max 100 mg/dose) |
| Duration | 60 days |
| Notes | Life-saving indication overrides dental concerns |
Secondary Paediatric Indications (Off-label)
| Indication | Age | Dose | Duration | Notes |
|---|---|---|---|---|
|
Mycoplasma pneumoniae pneumonia
|
≥8 years | 2 mg/kg twice daily (max 100 mg/dose) | 7–10 days | OFF-LABEL; when macrolide-resistant suspected |
|
Acne vulgaris (moderate–severe)
|
≥12 years | 50–100 mg once daily | 6–12 weeks | OFF-LABEL; with topical therapy |
Safety Monitoring in Paediatrics
- Monitor for GI upset; administer with food if needed
- Advise upright posture for 30 minutes post-dose
- Sun protection during treatment
- Dental surveillance if used in children <8 years
- Document indication clearly when used off-label or in younger children
Renal Adjustments
No dose adjustment required for most patients.
| Renal Function | Recommendation |
|---|---|
| eGFR >30 mL/min | No adjustment needed |
| eGFR 10–30 mL/min | Standard dose acceptable for short courses; avoid prolonged therapy |
| eGFR <10 mL/min | Use with caution; standard dose acceptable but monitor for accumulation |
| Haemodialysis | Not significantly removed; no supplemental dose required |
| Peritoneal dialysis | Not significantly removed; standard dosing |
| CRRT | Standard dosing; monitor clinically |
Clinical Note: Unlike other tetracyclines, doxycycline is primarily excreted via GI tract (chelated in intestines), making it safer in renal impairment.
Hepatic adjustment
Contraindications
- Known hypersensitivity to doxycycline, any tetracycline, or excipients
- Pregnancy (second and third trimesters) — absolute contraindication
- Children <8 years — relative contraindication (except life-threatening infections under specialist care)
- Concurrent use with systemic retinoids (isotretinoin, acitretin) — risk of benign intracranial hypertension
- Myasthenia gravis — may exacerbate weakness (use only if no alternative and with close monitoring)
Cautions
- Oesophageal injury: Administer with adequate water; maintain upright posture for 30 minutes; avoid bedtime dosing
- Photosensitivity: Advise sun avoidance and protective measures
- First trimester pregnancy: Use only if no safer alternative and benefit outweighs risk
- Systemic lupus erythematosus: May exacerbate; use with caution
- History of oral/oesophageal surgery or strictures
- Concurrent hepatotoxic drugs
- Prolonged use: Risk of superinfection (Candida, Clostridioides difficile)
- Intracranial hypertension history
Pregnancy
| Parameter | Details |
|---|---|
| Risk Category |
Contraindicated in 2nd and 3rd trimesters
|
| Risk Summary | Crosses placenta; causes permanent teeth discoloration (yellow-brown), enamel hypoplasia, and inhibition of bone growth in fetus |
| First Trimester | Limited data; may be used if benefits clearly outweigh risks and no alternative exists |
| Preferred Alternatives | Azithromycin (for chlamydia, atypicals), Amoxicillin (for respiratory infections), Penicillin (for syphilis), Ceftriaxone (for gonorrhoea) |
| When May Be Used | Life-threatening maternal infection with no suitable alternative (e.g., rickettsial disease) — specialist decision |
| Monitoring | If inadvertent exposure, counsel regarding risks; no specific fetal monitoring indicated |
Lactation
| Parameter | Details |
|---|---|
| Compatibility |
Generally compatible for short courses
|
| Milk Levels | Low; minimal excretion into breast milk |
| Infant Absorption | Poorly absorbed by infant due to chelation with milk calcium |
| Preferred Alternatives | Azithromycin (if appropriate for indication) |
| Infant Monitoring | Observe for oral candidiasis, loose stools; theoretical dental staining risk with prolonged maternal use is very low |
| Recommendation | Short courses (≤3 weeks) acceptable during breastfeeding; avoid prolonged therapy if possible |
Elderly
| Parameter | Recommendation |
|---|---|
| Starting Dose | Standard adult dosing (100 mg once or twice daily) |
| Titration | Not applicable |
| Special Considerations | Higher risk of oesophageal ulceration — ensure adequate hydration and upright posture; monitor for pill oesophagitis symptoms (dysphagia, odynophagia, retrosternal pain) |
| Renal Function | No dose adjustment typically needed |
| Drug Interactions | Review concurrent medications (antacids, iron, calcium supplements, anticoagulants) |
| Adverse Effects | Monitor for Clostridioides difficile infection; may be more susceptible |
Major drug interactions
| Interacting Drug | Effect | Mechanism | Recommendation |
|---|---|---|---|
|
Isotretinoin / Acitretin
|
Risk of benign intracranial hypertension (pseudotumour cerebri) | Additive effect on intracranial pressure |
AVOID combination
|
|
Methotrexate
|
Increased methotrexate toxicity | Decreased renal clearance; displaced protein binding |
Avoid or use with extreme caution; monitor closely
|
|
Warfarin / Acenocoumarol
|
Enhanced anticoagulant effect; increased bleeding risk | Altered gut flora reducing vitamin K synthesis; possible CYP inhibition |
Monitor INR closely; may need warfarin dose reduction
|
|
Ciclosporin
|
Increased ciclosporin levels | Unknown mechanism |
Monitor ciclosporin levels
|
|
Antacids (Al/Mg/Ca-containing)
|
Markedly reduced doxycycline absorption | Chelation in GI tract |
Separate by at least 2–3 hours
|
|
Oral iron preparations
|
Reduced absorption of both drugs | Mutual chelation |
Separate by at least 2–3 hours
|
|
Calcium supplements / Dairy
|
Reduced doxycycline absorption | Chelation |
Separate by 2 hours; or take doxycycline with low-calcium meal
|
|
Sucralfate
|
Reduced doxycycline absorption | Physical binding |
Separate by at least 2 hours
|
|
Quinapril
|
Reduced quinapril absorption | Contains magnesium carbonate excipient |
Separate administration
|
| Interacting Drug | Effect | Recommendation |
|---|---|---|
|
Rifampicin
|
Reduced doxycycline levels (half-life reduced by ~50%) | May need doxycycline 100 mg twice daily instead of once daily; monitor clinical response |
|
Phenytoin / Carbamazepine / Phenobarbital
|
Reduced doxycycline efficacy | Enzyme induction; consider higher doxycycline dose or twice daily dosing |
|
Oral contraceptives
|
Theoretical reduced efficacy (controversial) | Limited evidence; advise additional contraception during antibiotic course and 7 days after (as per standard practice) |
|
Theophylline
|
Possible increased GI adverse effects | Monitor for nausea, vomiting |
|
Digoxin
|
Possible increased digoxin levels (in ~10% patients) | Monitor digoxin levels if signs of toxicity |
|
Penicillins
|
Possible antagonism (bacteriostatic vs bactericidal) | Clinical significance uncertain; avoid in severe infections like endocarditis/meningitis if possible |
|
Lithium
|
Possible increased lithium levels | Monitor lithium levels |
|
Kaolin-pectin antidiarrhoeals
|
Reduced doxycycline absorption | Separate by 2 hours |
Common Adverse effects
- Nausea, vomiting
- Epigastric discomfort, dyspepsia
- Diarrhoea
- Photosensitivity (phototoxic dermatitis)
- Oesophageal irritation / ulceration
- Vaginal candidiasis
- Oral candidiasis (thrush)
- Headache
- Skin rash (non-serious)
Serious Adverse effects
| Adverse Effect | Clinical Notes |
|---|---|
|
Benign intracranial hypertension (pseudotumour cerebri)
|
Headache, visual disturbances, papilloedema; discontinue immediately
|
|
Stevens-Johnson syndrome / Toxic epidermal necrolysis
|
Rare; discontinue immediately; hospitalisation required
|
|
Drug-induced hepatotoxicity
|
Monitor LFTs; discontinue if significant elevation |
|
Clostridioides difficile colitis
|
May occur during or weeks after therapy; discontinue and treat appropriately |
|
Severe photosensitivity / phototoxic bullous eruption
|
Discontinue; supportive care |
|
Oesophageal ulceration / stricture
|
Odynophagia, retrosternal pain; prevention is key |
|
Exacerbation of myasthenia gravis
|
Worsening weakness; avoid in known MG |
|
Hypersensitivity reactions / Anaphylaxis
|
Rare; standard management |
|
Permanent teeth discoloration
|
In children <8 years; enamel hypoplasia |
Monitoring requirements
| Timing | Parameters |
|---|---|
|
Baseline
|
LFTs if prolonged course planned (>2–3 weeks); renal function (for drug interaction assessment, not dose adjustment) |
|
During Therapy
|
Clinical response; signs of oesophageal irritation; skin for photosensitivity; signs of superinfection |
|
Long-term Use (>3 months)
|
LFTs every 2–3 months; monitor for C. difficile symptoms; periodic dental check in younger patients |
|
If on Anticoagulants
|
INR within 3–5 days of starting and after stopping |
|
Symptoms of Intracranial Hypertension
|
Immediate ophthalmological evaluation if headache, visual changes, papilloedema |
Brands in India
| Doxt | Dr. Reddy's | Capsules 100 mg |
|---|---|---|
| Doxycee | Cipla | Capsules 100 mg |
| Doxy-1 | Micro Labs | Capsules/Tablets 100 mg |
| Microdox | Micro Labs | Capsules 100 mg |
| Doxrid | Ridley Life Sciences | Capsules 100 mg |
| Biodoxi | Biochem | Capsules 100 mg |
| Tetradox | Alkem | Capsules 100 mg |
| Doxybond | Mankind | Capsules 100 mg |
| Doxiford | Intas | Capsules 100 mg |
Fixed-Dose Combinations (Common)
| Brand Name | Combination | Use |
|---|---|---|
| Doxt-SL | Doxycycline + Lactobacillus | GI protection |
Price range (INR)
| Formulation | Approximate Price | Notes |
|---|---|---|
| Capsules 100 mg (strip of 10) | ₹50–120 | Wide brand variation |
| Tablets 100 mg (strip of 10) | ₹40–100 | |
| Injection 100 mg vial | ₹80–200 | Limited use |
- NLEM Status: Doxycycline is included in National List of Essential Medicines (NLEM) 2022
- DPCO Price Control: Subject to price ceiling under DPCO
- Government Supply: Available in public health facilities under national programmes (NVBDCP, RNTCP TB-HIV)
Clinical pearls
- First-line for scrub typhus — Critical to recognise rickettsial illness in endemic areas (Himalayan belt, NE India, South India); do not wait for serology to initiate treatment in clinically suspected cases
- Take upright with full glass of water — Most common preventable ADR is oesophageal ulceration; advise patients to remain upright 30 minutes post-dose and avoid bedtime administration
- Food minimally affects absorption — Unlike other tetracyclines, doxycycline can be given with food to reduce GI upset (except high-calcium meals/dairy)
- Photosensitivity counselling — Less photosensitive than other tetracyclines but still significant; advise sunscreen SPF 30+, protective clothing, avoidance of prolonged sun exposure
- Preferred tetracycline in renal impairment — Primary excretion via intestinal chelation, not kidneys; safe to use without dose adjustment in CKD
- STI syndromic management — For urethral/cervical discharge, combine with ceftriaxone 250 mg IM (single dose) to cover both gonorrhoea and chlamydia per NACO guidelines
- Acne duration — Limit oral antibiotic courses to 6–12 weeks; always combine with topical retinoid and benzoyl peroxide to reduce resistance emergence
Version
RxIndia v0.1 — 27 Jan 2025
Reference
-
- CDSCO approved prescribing information for Doxycycline
- Indian Pharmacopoeia 2022
- NLEM India 2022
- NCDC Treatment Modules — Scrub Typhus, Cholera, Plague
- NVBDCP Guidelines — Malaria Chemoprophylaxis and Treatment
- NACO STI/RTI Technical Guidelines 2014 (updated)
- ICMR — Rickettsial Disease Guidelines
- API Textbook of Medicine (11th Edition) — Rickettsial infections, Leptospirosis, Brucellosis
- IAP Textbook of Pediatrics — Antimicrobial dosing
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (14th Edition)
- Harrison's Principles of Internal Medicine (21st Edition)
- BLISTER trial (off-label bullous pemphigoid reference)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.